Working… Menu

The Effect of Spironolactone on Blood Pressure in Type-2 Diabetics With Resistant Hypertension (SDHDS)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT01062763
Recruitment Status : Completed
First Posted : February 4, 2010
Results First Posted : May 8, 2014
Last Update Posted : May 8, 2014
Information provided by (Responsible Party):
Ib Abildgaard Jacobsen, Odense University Hospital

Brief Summary:
The purpose of this study is to estimate the effect of spironolactone on blood pressure resistant to therapy in type-2 diabetics.

Condition or disease Intervention/treatment Phase
Arterial Hypertension Hypertension, Resistant to Conventional Therapy Diabetes Mellitus Drug: spironolactone Drug: placebo Phase 3

Detailed Description:

The primary object of the study is to estimate the effect of addition of low dose spironolactone to antihypertensive treatment with at least three antihypertensive drugs in patients with type-2 diabetes and blood pressure over 130/80 mmHg.

Secondary aims are to estimate how many of these patients have their blood pressure controlled by the addition of spironolactone, to investigate whether the addition of spironolactone affects insulin sensitivity and urinary protein secretion and to estimate the incidence of adverse effects of the aldosterone antagonist.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 119 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: South Danish Hypertension and Diabetes Study
Study Start Date : March 2010
Actual Primary Completion Date : March 2012
Actual Study Completion Date : May 2012

Resource links provided by the National Library of Medicine

Arm Intervention/treatment
Experimental: addition of spironolactone
spironolactone is added to previous antihypertensive treatment
Drug: spironolactone
25 to 50 mg once daily

Placebo Comparator: Placebo
Addition of placebo
Drug: placebo
addition of placebo 1 to 2 tablets daily

Primary Outcome Measures :
  1. Change of of Systolic Blood Pressure [ Time Frame: 4 months ]
    Change of systolic blood pressure from baseline to study end at four months.

  2. Change of Diastolic Blood Pressure [ Time Frame: 4 months ]
    Change of diastolic blood pressure from baseline to study end at four months.

Secondary Outcome Measures :
  1. Adverse Effects [ Time Frame: 4 months ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years to 75 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Age < 75 years
  • Type-2 diabetes
  • Therapy resistant hypertension (by ABPM)
  • Treatment with at least 3 antihypertensives

Exclusion Criteria:

  • HbA1c > 10.0
  • BP > 180/110 mmHg
  • Secondary hypertension
  • Intolerance to spironolactone
  • Permanent treatment with nonsteroidal antiinflammatory drugs or systemic glucocorticoids
  • Total cholesterol 10 mmol/l
  • New York Heart Association class III and IV
  • Pregnancy or planned pregnancy
  • Psychiatric disease
  • Malignant disease
  • Insufficient adherence

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT01062763

Sponsors and Collaborators
Ib Abildgaard Jacobsen
Layout table for investigator information
Principal Investigator: Ib A Jacobsen, DMSc Odense University Hospital
Publications automatically indexed to this study by Identifier (NCT Number):
Layout table for additonal information
Responsible Party: Ib Abildgaard Jacobsen, Consultant physician, associate professor, Odense University Hospital Identifier: NCT01062763    
Other Study ID Numbers: EudraCT 2009-017033-22
2009-017033-22 ( EudraCT Number )
First Posted: February 4, 2010    Key Record Dates
Results First Posted: May 8, 2014
Last Update Posted: May 8, 2014
Last Verified: April 2014
Keywords provided by Ib Abildgaard Jacobsen, Odense University Hospital:
antihypertensive treatment
Type-2 diabetes
Additional relevant MeSH terms:
Layout table for MeSH terms
Vascular Diseases
Cardiovascular Diseases
Mineralocorticoid Receptor Antagonists
Hormone Antagonists
Hormones, Hormone Substitutes, and Hormone Antagonists
Physiological Effects of Drugs
Diuretics, Potassium Sparing
Natriuretic Agents